Business Wire

ASM Global’s Savor Team USA Heads to Singapore to Vie for Global Title in World’s Only Young Chef Young Waiter and Mixologist Competition

9.8.2024 16:00:00 EEST | Business Wire | Press release

Share

ASM Global’s culinary division SAVOR, which provides elevated food experiences for the globe’s most prestigious arenas, stadiums, convention/exhibition centers and performing arts venues, has announced the national winners of the American round of the world’s only competition for young culinary and hospitality talent.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240809474691/en/

Mixologist Winner Marco Guillen, Four Seasons, Napa Valley, California. (Photo: Business Wire)

Thomas Mendel, chef from Hamel Winery; Jaclyn Bisantz, waitress from Harbor House; and Marco Guillen, mixologist from Four Seasons Napa, were crowned as winners of the U.S. leg of the renowned World Young Chef Young Waiter Young Mixologist (WorldYYY) competition — the only event of its kind.

“This syncs very nicely with the work ASM Global does nationally to develop deep relationships with our local communities and reach out to educate, train and employ culinary talent via scholarship, internship and apprenticeship programs,” said Shaun Beard, SAVOR’s senior vice present of food and beverage.

“As ASM Global continues to elevate the food experience in many of the world’s premiere venues, these up-and-coming talents will be part of our universe,” Beard said. “The composure, creativity and determination we’ve seen from all the competitors in this high-pressure situation was truly unmatched and is proof that we have so much to look forward to from these young stars. We are proud to help pave the way for them and are excited to see what they do next.”

SAVOR’s Team USA members will next compete in the WorldYYY finals at Swissôtel The Stamford in Singapore this November. They will showcase their abilities to world-class chefs, hospitality experts and esteemed mixologists. A total of 36 contestants from 12 countries will compete for the world titles of Best Young Chef, Young Waiter and Young Mixologist.

The finals ofYYY USA recently took place at the prestigious The Culinary Institute of America at Copia (CIA) in Napa, California, with a panel of expert judges, including Master Chef Roland Passot, propriétaire and chief culinary officer; Tournament of Champions’ Tracey Shepos Cenami, executive chef and cheese specialist at Kendall-Jackson Wine Estate and Gardens; and Food Network Chef Adam Sobel, partner of Mina Group anointing the winners.

ASM Global’s SAVOR division became a strategic partner of the competition nearly five years ago as part of its worldwide commitment to nurturing and identifying new talent, introducing them to the hospitality space and showcasing them to renowned culinary industry leaders.

About SAVOR

SAVOR is the culinary division of ASM Global, the world’s No. 1 development and full-service venue company with a portfolio of more than 400 of the world’s most prestigious arenas, stadiums, convention/exhibition centers and performing arts venues network spanning five continents. The team at SAVOR provides elevated and curated guest experiences at every event, from the food preparation to the beverage offerings, whether for intimate VIP experiences or banquets with over 20,000 guests. In addition to authentic, chef-driven food, the core elements of SAVOR's food vision include partnerships with local growers, producers and community members; a commitment to using antibiotic-free meats and poultry; and dedication to minimizing impact on the environment through robust sustainability, recycling and composting programs. For more information, please visit savorasmglobal.com.

About YYY

Since its establishment in 1979, the Young Chef Young Waiter competition has continued to promote hospitality as a career of choice, a profession and a vocation. Today, with its new revitalized format, Young Chef Young Waiter continues to honor the next culinary and service stars globally. World Young Chef Young Waiter Young Mixologist’s, in partnership with Great Campaign U.K. and Northern Ireland and The Culinary Institute of America, mission is to discover the best young talents in the industry. The competition is open to young chefs, waiters and mixologists age 28 and under from diverse backgrounds. YYY ensures these young talents are equipped with relevant skills, current knowledge and a network to help them succeed in the world of hospitality.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240809474691/en/

Contacts

Jim Yeager
breakwhitelight (for ASM Global)
jim@breakwhitelight.com
Mobile: 818-264-6812

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye